JP2022529943A5 - - Google Patents
Info
- Publication number
- JP2022529943A5 JP2022529943A5 JP2021561663A JP2021561663A JP2022529943A5 JP 2022529943 A5 JP2022529943 A5 JP 2022529943A5 JP 2021561663 A JP2021561663 A JP 2021561663A JP 2021561663 A JP2021561663 A JP 2021561663A JP 2022529943 A5 JP2022529943 A5 JP 2022529943A5
- Authority
- JP
- Japan
- Prior art keywords
- interferon
- type
- composition according
- directed
- target
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025032100A JP2025084914A (ja) | 2019-04-15 | 2025-02-28 | がんの処置における使用のための、標的指向性のマスクされたｉ型インターフェロン（ｉｆｎａおよびｉｆｎｂ）と腫瘍抗原に対する抗体とを含む融合タンパク質組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962920140P | 2019-04-15 | 2019-04-15 | |
| US62/920,140 | 2019-04-15 | ||
| PCT/US2020/028296 WO2020214690A1 (en) | 2019-04-15 | 2020-04-15 | Fusion protein composition(s) comprising targeted masked type i interferons (ifna and ifnb) and an antibody against tumor antigen, for use in the treatment of cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025032100A Division JP2025084914A (ja) | 2019-04-15 | 2025-02-28 | がんの処置における使用のための、標的指向性のマスクされたｉ型インターフェロン（ｉｆｎａおよびｉｆｎｂ）と腫瘍抗原に対する抗体とを含む融合タンパク質組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022529943A JP2022529943A (ja) | 2022-06-27 |
| JP2022529943A5 true JP2022529943A5 (https=) | 2023-04-19 |
Family
ID=70554222
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021561663A Pending JP2022529943A (ja) | 2019-04-15 | 2020-04-15 | がんの処置における使用のための、標的指向性のマスクされたｉ型インターフェロン（ｉｆｎａおよびｉｆｎｂ）と腫瘍抗原に対する抗体とを含む融合タンパク質組成物 |
| JP2025032100A Pending JP2025084914A (ja) | 2019-04-15 | 2025-02-28 | がんの処置における使用のための、標的指向性のマスクされたｉ型インターフェロン（ｉｆｎａおよびｉｆｎｂ）と腫瘍抗原に対する抗体とを含む融合タンパク質組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025032100A Pending JP2025084914A (ja) | 2019-04-15 | 2025-02-28 | がんの処置における使用のための、標的指向性のマスクされたｉ型インターフェロン（ｉｆｎａおよびｉｆｎｂ）と腫瘍抗原に対する抗体とを含む融合タンパク質組成物 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US11136353B2 (https=) |
| EP (1) | EP3955957A1 (https=) |
| JP (2) | JP2022529943A (https=) |
| KR (1) | KR20210153092A (https=) |
| CN (1) | CN113993540A (https=) |
| AU (1) | AU2020258384A1 (https=) |
| CA (1) | CA3136602A1 (https=) |
| WO (1) | WO2020214690A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010215761B2 (en) * | 2009-02-23 | 2017-04-06 | Cytomx Therapeutics, Inc | Proproteins and methods of use thereof |
| WO2020023702A1 (en) | 2018-07-25 | 2020-01-30 | AskGene Pharma, Inc. | Novel il-21 prodrugs and methods of use thereof |
| CA3141626A1 (en) | 2019-06-12 | 2020-12-17 | AskGene Pharma, Inc. | Novel il-15 prodrugs and methods of use thereof |
| CA3165927A1 (en) | 2020-01-11 | 2021-07-15 | AskGene Pharma, Inc. | Novel masked cytokines and methods of use thereof |
| WO2021207669A1 (en) | 2020-04-10 | 2021-10-14 | Cytomx Therapeutics, Inc. | Activatable cytokine constructs and related compositions and methods |
| IL298136A (en) | 2020-05-13 | 2023-01-01 | Bonum Therapeutics Inc | Preparations of protein complexes and methods of using them |
| US20240076355A1 (en) * | 2021-01-14 | 2024-03-07 | AskGene Pharma, Inc. | Interferon Prodrugs and Methods of Making and Using the Same |
| BR112023018735A2 (pt) | 2021-03-16 | 2023-11-28 | Cytomx Therapeutics Inc | Construtos de citocinas ativáveis mascarados e composições e métodos relacionados |
| CA3221878A1 (en) | 2021-06-18 | 2022-12-22 | David Stover | Fusion protein composition(s) comprising masked type i interferons (ifna and ifnb) for use in the treatment of cancer and methods thereof |
| CN118647629A (zh) * | 2021-09-28 | 2024-09-13 | 苏州格治生物科技有限公司 | 含有TNF-α的免疫缀合物及其相关方法和组合物 |
| CN115057946B (zh) * | 2022-06-30 | 2023-05-16 | 四川省医学科学院·四川省人民医院 | 干扰素在制备抗广谱流感病毒和冠状病毒药物中的应用 |
| TW202502388A (zh) | 2023-03-02 | 2025-01-16 | 日商大鵬藥品工業股份有限公司 | 包含抗cd138抗體之抗體藥物複合體 |
| WO2025201363A1 (zh) * | 2024-03-27 | 2025-10-02 | 高雄医学大学 | 细胞因子阻断抗体及其应用 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US5476996A (en) | 1988-06-14 | 1995-12-19 | Lidak Pharmaceuticals | Human immune system in non-human animal |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| FR2646438B1 (fr) | 1989-03-20 | 2007-11-02 | Pasteur Institut | Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration |
| US6657103B1 (en) | 1990-01-12 | 2003-12-02 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| ATE158021T1 (de) | 1990-08-29 | 1997-09-15 | Genpharm Int | Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
| US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| ES2297889T3 (es) | 1997-07-14 | 2008-05-01 | Bolder Biotechnology, Inc. | Derivados de hormona de crecimiento y proteinas relacionadas. |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| RU2262510C9 (ru) | 1999-05-19 | 2006-04-20 | Лексиген Фармасьютикэлс Корп. | Слитый белок, обладающий биологической активностью интерферона-альфа, димерный слитый белок, фармацевтическая композиция, их содержащая, молекула днк (варианты) и способ адресования интерферона-альфа в ткани печени |
| US20040014652A1 (en) | 2000-06-01 | 2004-01-22 | Andre Trouet | Tumor activated prodrug compounds and methods of making and using the same |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US7105348B2 (en) | 2000-10-31 | 2006-09-12 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| CA2430013C (en) | 2000-11-30 | 2011-11-22 | Medarex, Inc. | Transgenic transchromosomal rodents for making human antibodies |
| KR20050107435A (ko) | 2003-02-18 | 2005-11-11 | 메르크 파텐트 게엠베하 | 개선된 특성의 인터페론 알파 뮤테인의 융합 단백질 |
| KR101225299B1 (ko) | 2003-12-10 | 2013-01-24 | 메다렉스, 인코포레이티드 | 인터페론 알파 항체 및 그의 용도 |
| HUE027902T2 (en) | 2004-02-09 | 2016-11-28 | Human Genome Sciences Inc Corp Service Company | Albumin fusion proteins |
| BRPI0509274A (pt) | 2004-03-26 | 2007-09-04 | Pfizer Prod Inc | usos de anticorpos anti-ctla-4 |
| WO2006031811A2 (en) | 2004-09-10 | 2006-03-23 | Neose Technologies, Inc. | Glycopegylated interferon alpha |
| AU2006255122B2 (en) | 2005-06-03 | 2010-10-21 | Ambrx, Inc. | Improved human interferon molecules and their uses |
| WO2008091311A1 (en) | 2007-01-26 | 2008-07-31 | Synageva Biopharma Corp | Transgene expression in avians |
| BRPI0814465B1 (pt) | 2007-07-26 | 2021-11-23 | Novagen Holding Corporation | Proteína de fusão, dímero, método para produzir uma proteína de fusão, linhagem de célula, usos de uma proteína de fusão e de uma composição farmacêutica e composição farmacêutica |
| CN101868246A (zh) | 2007-09-21 | 2010-10-20 | 加利福尼亚大学董事会 | 被导靶的干扰素显示强的细胞凋亡和抗肿瘤活性 |
| US9272029B2 (en) | 2009-03-26 | 2016-03-01 | Ibc Pharmaceuticals, Inc. | Interferon lambada-antibody complexes |
| EP2116768B1 (en) | 2008-05-09 | 2016-07-27 | Alstom Technology Ltd | Burner |
| RU2636046C2 (ru) | 2009-01-12 | 2017-11-17 | Сайтомкс Терапьютикс, Инк | Композиции модифицированных антител, способы их получения и применения |
| AU2010215761B2 (en) * | 2009-02-23 | 2017-04-06 | Cytomx Therapeutics, Inc | Proproteins and methods of use thereof |
| CN102413843A (zh) | 2009-03-05 | 2012-04-11 | 阿森迪斯药物股份有限公司 | 干扰素α载体前药 |
| WO2011064758A2 (en) | 2009-11-30 | 2011-06-03 | Pfizer Limited | Fusion protein |
| PT2646464E (pt) | 2010-12-03 | 2015-10-05 | Adamed Sp Zoo | Proteína de fusão anticancerígena |
| GB201203442D0 (en) * | 2012-02-28 | 2012-04-11 | Univ Birmingham | Immunotherapeutic molecules and uses |
| PT2822575T (pt) | 2012-03-03 | 2020-07-02 | Immungene Inc | Moléculas de fusão anticorpos-mutante de interferão modificadas |
| US9803021B2 (en) | 2012-12-07 | 2017-10-31 | The Regents Of The University Of California | CD138-targeted interferon demonstrates potent apoptotic and anti-tumor activities |
| EP2984171A2 (en) | 2013-04-10 | 2016-02-17 | Skau Aps | Peptides having immune suppresive domains for transfection |
| LT6164B (lt) | 2013-10-15 | 2015-06-25 | Uab Biotechnologinės Farmacijos Centras "Biotechpharma" | Sulieti interferono-alfa 5 baltymai su kitu citokinu ir jų gamybos būdas |
| US10435695B2 (en) | 2016-09-08 | 2019-10-08 | The Government of the United States of America, as represented by the Secretary of Homeland Security | Fusion protein comprising Gaussia luciferase, translation interrupter sequence, and interferon amino acid sequences |
| JP2020528878A (ja) | 2017-06-20 | 2020-10-01 | ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム | がん治療用インターフェロンプロドラッグ |
-
2020
- 2020-04-15 EP EP20724309.8A patent/EP3955957A1/en active Pending
- 2020-04-15 AU AU2020258384A patent/AU2020258384A1/en active Pending
- 2020-04-15 JP JP2021561663A patent/JP2022529943A/ja active Pending
- 2020-04-15 WO PCT/US2020/028296 patent/WO2020214690A1/en not_active Ceased
- 2020-04-15 CN CN202080044080.4A patent/CN113993540A/zh active Pending
- 2020-04-15 US US16/849,889 patent/US11136353B2/en active Active
- 2020-04-15 KR KR1020217036953A patent/KR20210153092A/ko active Pending
- 2020-04-15 CA CA3136602A patent/CA3136602A1/en active Pending
-
2021
- 2021-09-02 US US17/465,727 patent/US11795198B2/en active Active
-
2023
- 2023-09-14 US US18/467,206 patent/US12162958B2/en active Active
-
2025
- 2025-02-28 JP JP2025032100A patent/JP2025084914A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022529943A5 (https=) | ||
| JP2025084914A (ja) | がんの処置における使用のための、標的指向性のマスクされたｉ型インターフェロン（ｉｆｎａおよびｉｆｎｂ）と腫瘍抗原に対する抗体とを含む融合タンパク質組成物 | |
| HRP20210876T1 (hr) | Anti-tmprss2 antitijela i fragmenti koji vezuju antigen | |
| CN110740754A (zh) | 一种抗间皮素抗体及其抗体药物缀合物 | |
| JP2021521822A5 (https=) | ||
| JP2022512043A5 (https=) | ||
| JP2020531043A5 (https=) | ||
| JP2022520998A5 (https=) | ||
| JP2018520092A5 (https=) | ||
| JP2021512151A5 (https=) | ||
| JP2019506869A5 (https=) | ||
| JP2003523771A5 (https=) | ||
| RU2018107427A (ru) | Однодоменное антитело и его производные белки к лиганду-1 белка программируемой смерти клеток(pdli) | |
| CN106714831A (zh) | 新的抗‑rnf43抗体和使用方法 | |
| HRP20120701T1 (hr) | Humana monoklonska protutijela protiv fukozil-gm1 i postupci za uporabu antifukozil-gm1 | |
| WO2018119118A4 (en) | Lymphotoxin-beta receptor-binding agents, targeting antibodies, and uses thereof | |
| EP4277707A1 (en) | Interferon prodrugs and methods of making and using the same | |
| CA2755686A1 (en) | Methods and compositions for bi-specific targeting of cd19/cd22 | |
| JP2019524640A5 (https=) | ||
| CN115916839A (zh) | 抗pdl1×egfr的双特异性抗体 | |
| JP2023544143A5 (https=) | ||
| Bera et al. | Comparison of recombinant immunotoxins against LeY antigen expressing tumor cells: influence of affinity, size, and stability | |
| HRP20161449T1 (hr) | Genski proizvodi koji su diferecijalno izraženi u tumorima i njihova primjena | |
| JP2024510811A5 (https=) | ||
| JP2024501767A5 (https=) |